 Fennec Pharmaceuticals Inc. NASDAQ:FENC; TSX: FRX, a specialty pharmaceutical company focused on the development of PEDMARKTM a unique formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric patients, today announced an amendment to its existing senior debt facility with the Life Sciences Group at Bridge Bank increasing the size of the facility from 12.5 million to 18 million. This amendment provides Fennec with an 18 million debt facility comprised of two term loans. 